Analysts expect Pasithea Therapeutics Corp. to report revenue of 0.00 for Q2 23, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q2 23 | Q3 23 | Q4 23 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | ||||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Pasithea Therapeutics Corp. to report earnings per share of -3.22 for Q2 23, against a range of -3.53 to -2.91. The most recent reported quarter, Q1 26, came in at -0.12, a 7.7% beat against the -0.13 consensus.
| Metric | Q2 23 | Q3 23 | Q4 23 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | - | -0.66 | -0.41 | -0.79 | -0.12 | - | - | - | - | - | ||||||||||
| High Estimate | -2.91 | -3.59 | -3.40 | - | - | -0.17 | -0.12 | -0.14 | -0.19 | -0.25 | 0.00 | -0.06 | ||||||||||
| Low Estimate | -3.53 | -3.91 | -3.92 | - | - | -0.19 | -0.14 | -0.16 | -0.23 | -0.27 | 0.00 | -0.06 | ||||||||||
| Consensus Estimate | -3.22 | -3.75 | -3.66 | - | - | -0.18 | -0.13 | -0.15 | -0.21 | -0.26 | 0.00 | -0.06 |